

Bijlage 10 – Referentielijst

1. Committee Practical Tuberculosis Control, *Guideline: Tuberculosis Source and Contact Investigation*. 2020, KNCV Tuberculosis Foundation: The Hague.
2. Tuberculose., N.V.v.A.v.L.e., *Richtlijn Medicamenteuze behandeling van tuberculose*. 2014; Available from: Richtlijn Medicamenteuze behandeling van tuberculose - NVALT | RIVM.
3. Spruijt, I., et al., *Tailored approaches facilitate high completion of tuberculosis infection treatment among migrants*. Eur Respir J, 2022. **59**(3).
4. *Verpleegkundige Anamneselijst (VAL) in de tbc-bestrijding*. 2018, V&VN: Utrecht.
5. *Verpleegkundige Anamneselijst (VAL-LTBI) in de tbc-bestrijding*. 2020, V&VN: Utrecht.
6. *Zelfredzaamheid-matrix*. 2017; Available from: <https://www.zelfredzaamheidmatrix.nl/>.
7. *Richtlijn: Medicatietrouw*. 2023, V&VN: Utrecht.
8. Gezondheidsvaardigheden, A. *Wat zijn lage gezondheidsvaardigheden?* 2024 [cited 2024; Available from: <https://www.gezondheidsvaardigheden.nl/aan-de-slag/agenderen/wat-zijn-gezondheidsvaardigheden>.
9. *WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-susceptible tuberculosis treatment*. 2022. Licence: CC BY-NC-SA 3.0 IGO., World Health Organization: Geneva.
10. *Tuberculose in Nederland: surveillance rapport 2022*. 2023, Rijksinstituut voor Volksgezondheid en Milieu: Bilthoven.
11. *Nationaal plan tuberculosebestrijding: Update 2021-2025*. 2021, Rijksinstituut voor Volksgezondheid en Milieu: Bilthoven.
12. Jansen-Aaldring, N., S. van de Berg, and S. van den Hof, *Patient support during treatment for active tuberculosis and for latent tuberculosis infection: Policies and practices in European low-incidence countries*. J Adv Nurs, 2018. **74**(12): p. 2755-2765.
13. Zomahoun, H.T.V., et al., *Effectiveness of motivational interviewing interventions on medication adherence in adults with chronic diseases: a systematic review and meta-analysis*. Int J Epidemiol, 2017. **46**(2): p. 589-602.
14. Foster, I., et al., *The role of counselling in tuberculosis diagnostic evaluation and contact tracing: scoping review and stakeholder consultation of knowledge and research gaps*. BMC Public Health, 2022. **22**(1): p. 190.
15. Tola, H.H., et al., *Psychological and Educational Intervention to Improve Tuberculosis Treatment Adherence in Ethiopia Based on Health Belief Model: A Cluster Randomized Control Trial*. PLoS One, 2016. **11**(5): p. e0155147.
16. Parwati, N.M., et al., *A Health Belief Model-Based Motivational Interviewing for Medication Adherence and Treatment Success in Pulmonary Tuberculosis Patients*. Int J Environ Res Public Health, 2021. **18**(24).
17. Law, S., et al., *Acceptability, feasibility, and impact of a pilot tuberculosis literacy and treatment counselling intervention: a mixed methods study*. BMC Infect Dis, 2021. **21**(1): p. 449.
18. Bachina, P., et al., *Programmatic Adoption and Implementation of Video-Observed Therapy in Minnesota: Prospective Observational Cohort Study*. JMIR Form Res, 2022. **6**(8): p. e38247.
19. Garfein, R.S., et al., *Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA*. Emerg Infect Dis, 2018. **24**(10): p. 1806-1815.
20. Perry, A., et al., *Real-world implementation of video-observed therapy in an urban TB program in the United States*. Int J Tuberc Lung Dis, 2021. **25**(8): p. 655-661.
21. Bommakanti, K.K., et al., *Requiring smartphone ownership for mHealth interventions: who could be left out?* BMC Public Health, 2020. **20**(1): p. 81.

22. Chuck, C., et al., *Enhancing management of tuberculosis treatment with video directly observed therapy in New York City*. Int J Tuberc Lung Dis, 2016. **20**(5): p. 588-93.
23. Al-Sahafi, A., et al., *Treatment outcomes among tuberculosis patients in Jeddah, Saudi Arabia: Results of a community mobile outreach directly observed Treatment, Short-course (DOTS) project, compared to a standard facility-based DOTS: A randomized controlled trial*. J Clin Tuberc Other Mycobact Dis, 2021. **22**: p. 100210.
24. Ricks, P.M., et al., *A randomized trial comparing standard outcomes in two treatment models for substance users with tuberculosis*. Int J Tuberc Lung Dis, 2015. **19**(3): p. 326-32.
25. Lutge, E.E., et al., *Incentives and enablers to improve adherence in tuberculosis*. Cochrane Database Syst Rev, 2015. **2015**(9): p. CD007952.
26. van Hoorn, R., et al., *The Effects of Psycho-Emotional and Socio-Economic Support for Tuberculosis Patients on Treatment Adherence and Treatment Outcomes - A Systematic Review and Meta-Analysis*. PLoS One, 2016. **11**(4): p. e0154095.
27. Richterman, A., et al., *Cash interventions to improve clinical outcomes for pulmonary tuberculosis: systematic review and meta-analysis*. Bull World Health Organ, 2018. **96**(7): p. 471-483.
28. Aragao, F.B.A., et al., *Impact of social protection programs on adults diagnosed with Tuberculosis: systematic review*. Rev Bras Enferm, 2021. **74**(3): p. e20190906.
29. Andrade, K.V.F., et al., *Effects of social protection on tuberculosis treatment outcomes in low or middle-income and in high-burden countries: systematic review and meta-analysis*. Cad Saude Publica, 2018. **34**(1): p. e00153116.
30. Mazza-Stalder, J., et al., *Improvement in Tuberculosis Outcomes With a Combined Medical and Social Approach*. Front Med (Lausanne), 2019. **6**: p. 135.
31. Izzard, A., et al., *Improved treatment completion for tuberculosis patients: The case for a dedicated social care team*. J Infect, 2021. **82**(3): p. e1-e3.
32. Tucker, A., et al., *Quantifying the need for enhanced case management for TB patients as part of TB cohort audit in the North West of England: a descriptive study*. BMC Public Health, 2017. **17**(1): p. 881.
33. *Richtlijn: Preventieve tuberculosebehandeling*. 2022, Commissie Praktische Tuberculosebestrijding (CPT): Bilthoven.
34. Allwood, B.W., et al., *Post-tuberculosis lung health: perspectives from the First International Symposium*. Int J Tuberc Lung Dis, 2020. **24**(8): p. 820-828.
35. Maleche-Obimbo, E., et al., *Magnitude and factors associated with post-tuberculosis lung disease in low- and middle-income countries: A systematic review and meta-analysis*. PLOS Glob Public Health, 2022. **2**(12): p. e0000805.
36. Romanowski, K., et al., *Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis*. Lancet Infect Dis, 2019. **19**(10): p. 1129-1137.
37. Fan, H., et al., *Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis*. Ann Transl Med, 2021. **9**(5): p. 390.
38. Migliori, G.B., et al., *ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update*. Eur Respir J, 2018. **51**(5).
39. Mademilov, M., et al., *What should pulmonary rehabilitation look like for people living with post-tuberculosis lung disease in the Bishkek and Chui region of the Kyrgyz Republic? A qualitative exploration*. BMJ Open, 2022. **12**(2): p. e053085.
40. Romanowski, K., P. Amin, and J.C. Johnston, *Improving post-tuberculosis care in Canada*. CMAJ, 2022. **194**(47): p. E1617-E1618.
41. Nightingale, R., et al., *Post-TB health and wellbeing*. Int J Tuberc Lung Dis, 2023. **27**(4): p. 248-283.
42. *Zorgstandaard Vroege opsporing psychische klachten en aandoeningen in de volwassen bevolking*. GGZ Standaarden 2022.

43. Committee Practical Tuberculosis Control, *Policy Infection Control Measures* 2021.
44. Sterne JAC, S.J., Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT., *RoB 2: a revised tool for assessing risk of bias in randomised trials*. 2019. **BMJ** 2019; **366**: l4898.
45. GA Wells, B.S., D O'Connell, J Peterson, V Welch, M Losos, P Tugwell,, *The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies*
46. Institute, J.B., *Checklist for Analytical Cross Sectional Studies*. 2017.
47. Babalik, A., et al., *A registry-based cohort study of pulmonary tuberculosis treatment outcomes in Istanbul, Turkey*. Jpn J Infect Dis, 2013. **66**(2): p. 115-20.
48. Kolifarhood, G., et al., *Spatial and non-spatial determinants of successful tuberculosis treatment outcomes: An implication of Geographical Information Systems in health policy-making in a developing country*. J Epidemiol Glob Health, 2015. **5**(3): p. 221-30.
49. Gafar, F., et al., *Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the Netherlands*. Eur Respir J, 2019. **54**(6).
50. Babalik, A., et al., *An investigation into the relationship between region specific quality of life and adverse tuberculosis treatment outcomes in Istanbul, Turkey*. Rev Port Pneumol, 2014. **20**(5): p. 248-53.
51. Costa-Veiga, A., T. Briz, and C. Nunes, *Unsuccessful treatment in pulmonary tuberculosis: factors and a consequent predictive model*. Eur J Public Health, 2018. **28**(2): p. 352-358.
52. Lee, S., et al., *Characteristics and Treatment Outcomes among Migrants with Pulmonary Tuberculosis: A Retrospective Cohort Study in Japan, 2009-2018*. Int J Environ Res Public Health, 2022. **19**(19).
53. Millett, E.R., et al., *Factors associated with being lost to follow-up before completing tuberculosis treatment: analysis of surveillance data*. Epidemiol Infect, 2013. **141**(6): p. 1223-31.
54. Stosic, M., et al., *Trends in tuberculosis notification and mortality and factors associated with treatment outcomes in Serbia, 2005 to 2015*. Euro Surveill, 2020. **25**(1).
55. Zhang, Q., M. Gaafer, and I. El Bayoumy, *Determinants of default from pulmonary tuberculosis treatment in Kuwait*. ScientificWorldJournal, 2014. **2014**: p. 672825.
56. Afshari, M., et al., *Treatment default and its related factors among tuberculosis patients, a case-control study in Iran*. GMS Hyg Infect Control, 2020. **15**: p. Doc33.
57. Alavi, S.M., et al., *Prevalence and treatment outcome of pulmonary and extrapulmonary pediatric tuberculosis in southwestern Iran*. Caspian J Intern Med, 2015. **6**(4): p. 213-9.
58. Coorey, N.J., et al., *Risk factors for TB in Australia and their association with delayed treatment completion*. Int J Tuberc Lung Dis, 2022. **26**(5): p. 399-405.
59. Evenden, P., et al., *Presentation and healthcare delays among people with tuberculosis in London, and the impact on treatment outcome*. BMJ Open Respir Res, 2019. **6**(1): p. e000468.
60. Pettit, A.C., et al., *Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis*. J Infect, 2013. **67**(5): p. 424-32.
61. Pradipta, I.S., et al., *Predictors for treatment outcomes among patients with drug-susceptible tuberculosis in the Netherlands: a retrospective cohort study*. Clin Microbiol Infect, 2019. **25**(6): p. 761 e1-761 e7.
62. Shahrezaei, M., M.R. Maracy, and F. Farid, *Factors Affecting Mortality and Treatment Completion of Tuberculosis Patients in Isfahan Province from 2006 to 2011*. Int J Prev Med, 2015. **6**: p. 91.
63. Vasankari, T., et al., *Treatment outcome of extra-pulmonary tuberculosis in Finland: a cohort study*. BMC Public Health, 2010. **10**: p. 399.

64. Stosic, M.B., et al., *Tuberculosis and associated risk factors among children and adolescent population in Serbia: 12 year's retrospective study*. J Infect Dev Ctries, 2021. **15**(6): p. 818-825.
65. Sultan, H., S. Haroon, and N. Syed, *Delay and completion of tuberculosis treatment: a cross-sectional study in the West Midlands, UK*. J Public Health (Oxf), 2013. **35**(1): p. 12-20.
66. Holden, M.A., et al., *Tuberculosis Treatment Completion Rates in Southern New Mexico Colonias*. J Immigr Minor Health, 2016. **18**(2): p. 330-6.
67. Guthmann, J.P., et al., *Tuberculosis treatment outcomes of notified cases: trends and determinants of potential unfavourable outcome, France, 2008 to 2014*. Euro Surveill, 2020. **25**(4).
68. Mitruka, K., et al., *Disparities in Tuberculosis Treatment Completion by Incarceration Status, U.S., 1999-2011*. Am J Prev Med, 2017. **52**(4): p. 483-490.
69. Rodrigo, T., et al., *A predictive scoring instrument for tuberculosis lost to follow-up outcome*. Respir Res, 2012. **13**(1): p. 75.
70. Kawatsu, L., et al., *A combination of quantitative and qualitative methods in investigating risk factors for lost to follow-up for tuberculosis treatment in Japan - Are physicians and nurses at a particular risk?* PLoS One, 2018. **13**(6): p. e0198075.
71. Korhonen, V., et al., *Risk factors affecting treatment outcomes for pulmonary tuberculosis in Finland 2007-2014: a national cohort study*. BMC Public Health, 2020. **20**(1): p. 1250.
72. Guthmann, J.P. and W. Haas, *Tuberculosis in the European Union/European Economic Area: much progress, still many challenges*. Euro Surveill, 2019. **24**(12).
73. Lucenko, I., et al., *Treatment outcomes among drug-susceptible tuberculosis patients in Latvia, 2006-2010*. Public Health Action, 2014. **4**(Suppl 2): p. S54-8.
74. Pettit, A.C., et al., *Non-adherence and drug-related interruptions are risk factors for delays in completion of treatment for tuberculosis*. Int J Tuberc Lung Dis, 2013. **17**(4): p. 486-92.
75. Bishara, H., et al., *Tuberculosis in native Israeli Arabs and Jews: trends and treatment outcomes, 1999-2011*. Epidemiol Infect, 2015. **143**(15): p. 3203-10.
76. Mor, Z., et al., *Tuberculosis diagnostic delay and therapy outcomes of non-national migrants in Tel Aviv, 1998-2008*. Euro Surveill, 2013. **18**(12).
77. Bishara, H., et al., *Cost of nurse-managed latent tuberculous infection treatment among hard-to-reach immigrants in Israel*. Int J Tuberc Lung Dis, 2015. **19**(7): p. 799-804.
78. Prater, C., S. Holzman, and M. Shah, *Programmatic Effectiveness of Latent Tuberculosis Care Cascade in a Community Health Center*. J Immigr Minor Health, 2021. **23**(3): p. 566-573.
79. Fiske, C.T., et al., *Risk factors for treatment default in close contacts with latent tuberculous infection*. Int J Tuberc Lung Dis, 2014. **18**(4): p. 421-7.
80. Fresard, I., et al., *Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis*. Swiss Med Wkly, 2011. **141**: p. w13240.
81. Goswami, N.D., et al., *Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study*. BMC Public Health, 2012. **12**: p. 468.
82. Morano, J.P., et al., *Latent tuberculosis infection: screening and treatment in an urban setting*. J Community Health, 2013. **38**(5): p. 941-50.
83. Trajman, A., et al., *Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment*. Int J Tuberc Lung Dis, 2010. **14**(5): p. 551-9.

84. Moro, R.N., et al., *Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada*. Clin Infect Dis, 2016. **62**(11): p. 1390-1400.
85. Sentis, A., et al., *Failure to complete treatment for latent tuberculosis infection in Portugal, 2013-2017: geographic-, sociodemographic-, and medical-associated factors*. Eur J Clin Microbiol Infect Dis, 2020. **39**(4): p. 647-656.
86. Sandul, A.L., et al., *High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection*. Clin Infect Dis, 2017. **65**(7): p. 1085-1093.
87. Hirsch-Moverman, Y., et al., *Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience*. Int J Tuberc Lung Dis, 2010. **14**(9): p. 1104-11.
88. Horsburgh, C.R., Jr., et al., *Latent TB infection treatment acceptance and completion in the United States and Canada*. Chest, 2010. **137**(2): p. 401-9.
89. Dobler, C.C. and G.B. Marks, *Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic*. PLoS One, 2012. **7**(11): p. e48900.
90. Kan, B., M. Kalin, and J. Bruchfeld, *Completing treatment for latent tuberculosis: patient background matters*. Int J Tuberc Lung Dis, 2013. **17**(5): p. 597-602.
91. Kawatsu, L., K. Uchimura, and A. Ohkado, *Trend and treatment status of latent tuberculosis infection patients in Japan - Analysis of Japan TB Surveillance data*. PLoS One, 2017. **12**(11): p. e0186588.
92. Schein, Y.L., et al., *Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study*. BMC Infect Dis, 2018. **18**(1): p. 587.
93. Hirsch-Moverman, Y., et al., *Latent tuberculous infection in the United States and Canada: who completes treatment and why?* Int J Tuberc Lung Dis, 2015. **19**(1): p. 31-8.
94. Holzman, S.B., et al., *Evaluation of the Latent Tuberculosis Care Cascade Among Public Health Clinics in the United States*. Clin Infect Dis, 2022. **75**(10): p. 1792-1799.
95. Li, J., et al., *Adherence to treatment of latent tuberculosis infection in a clinical population in New York City*. Int J Infect Dis, 2010. **14**(4): p. e292-7.
96. Nuzzo, J.B., et al., *Analysis of latent tuberculosis infection treatment adherence among refugees and other patient groups referred to the Baltimore City Health Department TB clinic, February 2009-March 2011*. J Immigr Minor Health, 2015. **17**(1): p. 56-65.
97. Erkens, C.G., et al., *Monitoring latent tuberculosis infection diagnosis and management in the Netherlands*. Eur Respir J, 2016. **47**(5): p. 1492-501.
98. Bruxvoort, K.J., et al., *Latent Tuberculosis Infection Treatment Practices in Two Large Integrated Health Systems in California, 2009-2018*. Open Forum Infect Dis, 2023. **10**(5): p. ofad219.
99. Gaensbauer, J., et al., *Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-based Tuberculosis Clinic*. Pediatr Infect Dis J, 2018. **37**(3): p. 224-228.
100. Macaraig, M.M., et al., *Improved treatment completion with shorter treatment regimens for latent tuberculous infection*. Int J Tuberc Lung Dis, 2018. **22**(11): p. 1344-1349.
101. McClintock, A.H., et al., *Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine*. BMC Infect Dis, 2017. **17**(1): p. 146.
102. Stantliff, T.M., et al., *The latent tuberculosis infection cascade of care during the COVID-19 pandemic response in a Mid-Sized US city*. J Clin Tuberc Other Mycobact Dis, 2023. **31**: p. 100367.

103. Chang, A.H., A. Polesky, and G. Bhatia, *House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study*. BMC Public Health, 2013. **13**: p. 894.
104. Chevrier, C., et al., *Introduction of short course treatment for latent tuberculosis infection at a primary care facility for refugees in Winnipeg, Canada: A mixed methods evaluation*. Front Public Health, 2022. **10**: p. 1064136.
105. Manful, A., et al., *Gaps in the care cascade for screening and treatment of refugees with tuberculosis infection in Middle Tennessee: a retrospective cohort study*. BMC Infect Dis, 2020. **20**(1): p. 592.
106. Campbell, J.I., et al., *Multicenter Analysis of Attrition from the Pediatric Tuberculosis Infection Care Cascade in Boston*. J Pediatr, 2023. **253**: p. 181-188 e5.
107. Holmes, R.H., et al., *Management of tuberculosis infection in Victorian children: A retrospective clinical audit of factors affecting treatment completion*. PLoS One, 2022. **17**(10): p. e0275789.
108. Yamin, A., et al., *Predictors of Latent Tuberculosis Infection Treatment After Introduction of a New Regimen: A Retrospective Cohort Study at an Inner City Clinic*. Open Forum Infect Dis, 2016. **3**(4): p. ofw082.
109. Haas, M.K., et al., *Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis*. Clin Infect Dis, 2021. **73**(9): p. e3459-e3467.
110. Jimenez-Fuentes, M.A., et al., *Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population*. Int J Tuberc Lung Dis, 2013. **17**(3): p. 326-32.
111. Kawatsu, L., K. Uchimura, and A. Ohkado, *Trend and treatment outcomes of latent tuberculosis infection among migrant persons in Japan: retrospective analysis of Japan tuberculosis surveillance data*. BMC Infect Dis, 2021. **21**(1): p. 42.
112. Sullivan, K., et al., *Seven-year retrospective study understanding the latent TB infection treatment cascade of care among adults in a low incidence country*. BMC Public Health, 2021. **21**(1): p. 964.
113. Codecasa, L.R., et al., *Isoniazid preventive treatment: predictors of adverse events and treatment completion*. Int J Tuberc Lung Dis, 2013. **17**(7): p. 903-8.
114. Cruz, A.T. and J.R. Starke, *Completion Rate and Safety of Tuberculosis Infection Treatment With Shorter Regimens*. Pediatrics, 2018. **141**(2).
115. Burzynski, J., et al., *In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence: A Randomized Noninferiority Trial*. JAMA Netw Open, 2022. **5**(1): p. e2144210.
116. Story, A., et al., *Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial*. Lancet, 2019. **393**(10177): p. 1216-1224.
117. Hirsch-Moverman, Y., et al., *Can a peer-based intervention impact adherence to the treatment of latent tuberculosis infection?* Int J Tuberc Lung Dis, 2013. **17**(9): p. 1178-85.
118. Hovell, M.F., et al., *Lessons learned from two interventions designed to increase adherence to LTBI treatment in Latino youth*. Contemp Clin Trials Commun, 2018. **12**: p. 129-136.
119. Johnston, J.C., et al., *The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial*. Eur Respir J, 2018. **51**(2).
120. Belknap, R., et al., *Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial*. Ann Intern Med, 2017. **167**(10): p. 689-697.
121. Onwubiko, U., et al., *Using Directly Observed Therapy (DOT) for latent tuberculosis treatment - A hit or a miss? A propensity score analysis of treatment completion among 274 homeless adults in Fulton County, GA*. PLoS One, 2019. **14**(6): p. e0218373.

122. Getahun, H., et al., *Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries*. Eur Respir J, 2015. **46**(6): p. 1563-76.